Replies to post #177100 on Biotech Values

[oc631]

for sure 493 will be moved into ph 3 ahead of 450 + 530

Perhaps demonstrating limited clinical activity of ABT-450 in GT3 patients can help support the filing of the more viable 493/530 protease-based combo. This seems counter-intuitive until you observe what's going on at GILD



http://www.clinicaltrials.gov/ct2/show/NCT01826981?term=ledipasvir&rank=13



Here GILD is testing LDV/SOF in GT3 patients. Why would GILD enroll GT3 patients after acknowledging that Ledipasvir has little activity within this genotype? GS-5816 was designed to overcome the limited activity of LDV in GT3. GILD might be planning to use LDV data to support the GS-5816/Sovaldi filing.